[go: up one dir, main page]

AU2001290312A1 - Peg-modified erythropoietin - Google Patents

Peg-modified erythropoietin

Info

Publication number
AU2001290312A1
AU2001290312A1 AU2001290312A AU9031201A AU2001290312A1 AU 2001290312 A1 AU2001290312 A1 AU 2001290312A1 AU 2001290312 A AU2001290312 A AU 2001290312A AU 9031201 A AU9031201 A AU 9031201A AU 2001290312 A1 AU2001290312 A1 AU 2001290312A1
Authority
AU
Australia
Prior art keywords
peg
epo
conjugated
native
erythropoietin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001290312A
Inventor
Hiromitsu Kawata
Minoru Machida
Hajime Miyamoto
Teruo Nakamura
Yasuo Sekimori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AU2001290312A1 publication Critical patent/AU2001290312A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides a polyethylene glycol-conjugated erythropoietin (PEG-conjugated EPO) prepared by PEG conjugation on the lysine residue at position 52 of native erythropoietin (native EPO). In order to achieve more sustained efficacy without losing physiological activities of native EPO, a glycoprotein rich in sugar chains, there has been a need to develop a PEG-conjugated EPO with significantly sustained efficacy by introducing a controlled number of PEG molecules at controlled positions. This PEG-conjugated EPO addresses such a need and provides more sustained efficacy.
AU2001290312A 2000-10-16 2001-09-28 Peg-modified erythropoietin Abandoned AU2001290312A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000315421 2000-10-16
JP2000-315421 2000-10-16
PCT/JP2001/008539 WO2002032957A1 (en) 2000-10-16 2001-09-28 Peg-modified erythropoietin

Publications (1)

Publication Number Publication Date
AU2001290312A1 true AU2001290312A1 (en) 2002-04-29

Family

ID=18794529

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001290312A Abandoned AU2001290312A1 (en) 2000-10-16 2001-09-28 Peg-modified erythropoietin

Country Status (8)

Country Link
US (2) US20040082765A1 (en)
EP (1) EP1333036B1 (en)
JP (1) JP5170931B2 (en)
AT (1) ATE421535T1 (en)
AU (1) AU2001290312A1 (en)
DE (1) DE60137525D1 (en)
ES (1) ES2320101T3 (en)
WO (1) WO2002032957A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1667708B9 (en) * 2002-12-26 2012-10-31 Mountain View Pharmaceuticals, Inc. POLYETHYLENE GLYCOL CONJUGATES OF INTERFERON-BETA-1b WITH ENHANCED IN VITRO BIOLOGICAL POTENCY
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
AU2003303634B2 (en) 2002-12-27 2009-10-01 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
CA2458085A1 (en) 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay
EP1471153A3 (en) * 2003-03-21 2005-06-15 F. Hoffmann-La Roche Ag Transcriptional activity assay
KR20060032140A (en) * 2003-05-30 2006-04-14 센토코 인코포레이티드 Formation of New Erythropoietin Conjugates Using Transglutaminase
US9539337B2 (en) * 2003-12-10 2017-01-10 Nektar Therapeutics Compositions comprising two different populations of polymer-active agent conjugates
JP4903580B2 (en) * 2003-12-30 2012-03-28 アウグスティヌス・バーダー Tissue regeneration law
WO2006089228A2 (en) * 2005-02-16 2006-08-24 Nektar Therapeutics Al, Corporation Conjugates of an epo moiety and a polymer
MX2007015819A (en) * 2005-06-13 2008-02-22 Nastech Pharm Co Transmucosal delivery of peptide derivatives.
IL169377A (en) 2005-06-23 2012-09-24 Avigdor Shafferman Uniformly conjugated serine hydrolases
WO2007026772A1 (en) * 2005-08-31 2007-03-08 Kaneka Corporation Transgenic avian which has foreign gene containing sequence encoding feline-derived protein and method for production thereof
US20080171696A1 (en) * 2005-10-21 2008-07-17 Avigenics, Inc. Pharmacodynamically enhanced therapeutic proteins
CU23556A1 (en) * 2005-11-30 2010-07-20 Ct Ingenieria Genetica Biotech POLYMER STRUCTURE SIMILAR TO DENDRÍMERO FOR THE OBTAINING OF CONJUGATES OF PHARMACEUTICAL INTEREST
US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
EP2010222A1 (en) 2006-03-31 2009-01-07 Baxter International Inc. Pegylated factor viii
US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
EP2630972B1 (en) 2006-07-25 2017-08-30 Lipoxen Technologies Limited N-terminal polysialylation
GB0615067D0 (en) * 2006-07-28 2006-09-06 Ttp Communications Ltd Reconfigurable signal processing scheme
PT2054074E (en) * 2006-08-04 2014-11-07 Prolong Pharmaceuticals Llc Modified erythropoietin
EP2532369B1 (en) 2006-12-15 2017-11-01 Baxalta GmbH Factor VIIa-(poly)sialic acid conjugate having prolonged in vivo half-life
US8101706B2 (en) 2008-01-11 2012-01-24 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
KR101486449B1 (en) 2008-01-11 2015-01-26 세리나 쎄라퓨틱스, 인코포레이티드 Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
GB0922354D0 (en) 2009-12-21 2010-02-03 Polytherics Ltd Novel polymer conjugates
PL3175863T3 (en) 2009-05-20 2022-03-21 Biomarin Pharmaceutical Inc. C-type natriuretic peptide variants
BR112012008341A2 (en) * 2009-09-15 2020-08-25 Kaneka Corporation modified erythropoietin to which water-soluble long chain molecule is added
WO2015130963A2 (en) 2014-02-27 2015-09-03 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5100664A (en) * 1985-09-20 1992-03-31 Cetus Corporation Human IL-2 as a vaccine adjuvant
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
JP2502646B2 (en) 1988-01-19 1996-05-29 松下電器産業株式会社 Burner
JPH029900A (en) * 1988-04-12 1990-01-12 Kirin Amgen Inc Modified erythropoetine
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
FI935485A7 (en) * 1992-12-09 1994-06-10 Ortho Pharma Corp PEG-hydrazone and PEG-oxime bond-forming reagents and their protein derivatives
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5747446A (en) * 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
ATE257844T1 (en) * 1995-03-10 2004-01-15 Nakamura Toshikazu HUMAN GROWTH FACTOR (HGF) ALTERED BY POLYETHYLENE GLYCOL
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
ATE341344T1 (en) * 1996-08-02 2006-10-15 Ortho Mcneil Pharm Inc POLYPEPTIDES WITH SINGLE COVALENTLY BONDED N-TERMINAL WATER SOLUBLE POLYMER
JP2001508783A (en) * 1997-01-29 2001-07-03 ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー PEGylation method
ATE375363T1 (en) * 1997-07-14 2007-10-15 Bolder Biotechnology Inc GROWTH HORMONE DERIVATIVES AND RELATED PROTEINS
WO2000032772A2 (en) * 1998-11-30 2000-06-08 Eli Lilly And Company Erythropoietic compounds
KR100731826B1 (en) * 1999-01-14 2007-06-22 볼더 바이오테크놀로지 인코퍼레이티드 Method for preparing a protein containing free cysteine residues
DE60004172T2 (en) 1999-01-29 2004-04-22 F. Hoffmann-La Roche Ag GCSF CONJUGATE
JO2291B1 (en) * 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythopintin derivatives
CZ299516B6 (en) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Erythropoietin glycoprotein conjugate, process for its preparation and use and pharmaceutical composition containing thereof

Also Published As

Publication number Publication date
JPWO2002032957A1 (en) 2004-02-26
EP1333036A1 (en) 2003-08-06
ES2320101T3 (en) 2009-05-19
JP5170931B2 (en) 2013-03-27
EP1333036A4 (en) 2004-09-29
US20060276634A1 (en) 2006-12-07
DE60137525D1 (en) 2009-03-12
US20040082765A1 (en) 2004-04-29
US8022191B2 (en) 2011-09-20
WO2002032957A1 (en) 2002-04-25
ATE421535T1 (en) 2009-02-15
EP1333036B1 (en) 2009-01-21

Similar Documents

Publication Publication Date Title
AU2001290312A1 (en) Peg-modified erythropoietin
WO2003055526A3 (en) Erythropoietin conjugates
AU2001296962A1 (en) Pegylated interleukin-10
IL206445A0 (en) Peptide conjugate of exendin-4(1-39)variant in combination with an antidiabetic agent for use in the treatment of type 2 diabetes mellitus
WO2000021574A3 (en) Site-directed dual pegylation of proteins
CA2174325A1 (en) Non-antigenic branched polymer conjugates
EP1454138A4 (en) Immunocytokines with modulated selectivity
DE3786000D1 (en) CONJUGATE POETS STAR.
WO1999004820A3 (en) Cytolysis of target cells by superantigen conjugates inducing t-cell activation
CA2283939A1 (en) Non-antigenic branched polymer conjugates
PT1264840E (en) Long lasting fusion peptide inhibitors of viral infection
WO2000012587A8 (en) Polyamide chains of precise length, methods to manufacture them and their conjugates
YU54301A (en) Gcsf conjugates
HK1049283A1 (en) Amphiphilic polymers and polypeptide conjugates comprising same
HK1042287A1 (en) Valency platform molecules comprising aminooxy groups
AU4660789A (en) Polypeptide derivatives
WO2000042973A3 (en) Homing pro-apoptotic conjugates and methods of using same
DK0557199T3 (en) Polyethylene Glycol-Hirudin Conjugates
CA2373252A1 (en) Long lasting anti-angiogenic peptides
TR200200599T2 (en) Human insulin monomeric analogues.
AU2001289923A1 (en) Conjugates of defined stoichiometry
WO2004014951A3 (en) Binding molecules
WO2004043884A3 (en) Novel acylating reagents
Yeboah The Caribbean's Silent Demographic Transition
TH52654A (en) Antiseptic-angiogenic peptides that are long-lived